Several drugs, including thiazolidinediones (peroxisome proliferator-activated receptor gamma (PPARγ) agonists that are insulin sensitizers) are being investigated as therapies to reduce hepatic steatosis, inflammation, and fibrosis [5,6]. Here, PPARG is linked to fatty liver disease.